In 2025, the Russian retail pharmaceutical market underwent significant reshuffling among its leading brands, largely driven by the performance of specific products. Within the top ten, only one brand maintained its previous ranking, while all others shifted positions. According to the “Audit of Retail Sales of Medicines in Russia (total sell-out)” database of the analytical company RNC Pharma, retail sales in 2025 covered 6,185 brands from 835 corporations. Compared with 2024, almost all products within the top 100 demonstrated growth in value terms. A decline in unit sales among the top 100 was recorded for only 24 brands.

At the end of 2025, the anticoagulant Eliquis by Pfizer ranked first among retail brands. The previous long-standing leader, Xarelto by Bayer, fell to third place under strong pressure from rivaroxaban generics. By the end of the year, 30 different manufacturers of generic alternatives were present in retail. Aggregate unit sales of generics increased 93-fold, while Xarelto’s sales declined by 22% both in value and in packages.

Meanwhile, second place was taken by Semavic from Geropharm, which climbed 18 positions year on year. Sales of the brand increased 2.7 times compared with the previous year, positioning it as a potential contender for first place.

Fourth position was occupied by Forxiga from AstraZeneca. Sales of the product grew by 54% in value terms, allowing it to move up five positions. Notably, Forxiga has demonstrated strong growth for several consecutive years, supported by expanded indications between 2020 and 2023. The drug is now indicated not only for diabetes but also for chronic heart failure and chronic kidney disease. It is worth noting that dozens of manufacturers are awaiting the expiration of dapagliflozin’s patent in Russia, with some already having engaged in legal disputes with the originator company.

Fifth place remained with Edarbi from Nizhpharm. This was the only product in the top ten that retained its ranking compared with 2024, while still demonstrating solid value growth of 26%. All other brands in the ranking, despite positive value dynamics, lost several positions compared with the previous year.

For example, Nurofen, which ranked third in 2024, dropped to sixth place, despite posting growth of 18% in value and 12% in packages. In general, the most noticeable losses were recorded among OTC products. Detralex from Servier moved down to seventh place, while Theraflu and Pentalgin each lost two positions, shifting to the lower end of the top ten. Among prescription drugs, Heptral also moved toward the bottom of the ranking despite positive sales dynamics. The brand Mexidol from Pharmasoft exited the top ten entirely, falling to twelfth place, although it still recorded growth of 7% in value and 4% in packages.

Within the top 100 brands overall, the most significant growth was demonstrated by products for diabetes and obesity treatment, particularly semaglutide-based medicines (Velgia, Queensenta), as well as tirzepatide (Tirzetta) from Promomed. Tirzetta entered retail distribution only in 2025 and had already reached 41st place by year-end.

Table. TOP-10 brands in the Russian retail pharmaceutical market in 2025 (value terms)